Aims & Scope
Clinical Skin Cancer is an international peer-reviewed, quarterly, journal dedicated to disseminating cutting-edge data to the practicing clinician by providing physicians and healthcare professionals with the most up-to-date, clinically relevant information available in order to enhance caregivers' ability to provide optimal care for their cancer patients.
Clinical Skin Cancer publishes original articles describing various aspects of clinical and translational research of skin malignancies and is devoted to articles on detection, diagnosis, prevention, and treatment of skin malignancies.
Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
Our mission is to be the premier source of clinically relevant information through promoting excellence in clinical research and facilitating the timely translation of that science to health care and clinical practice.
Key objectives to achieve these goals include the nurturing and development of future generations of clinical scientists, and the dissemination of new knowledge related to skin malignancies.
View Aims & ScopeAbstracting & Indexing
Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.
Subjects & Keywords
Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.
Most Cited Articles
The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.
-
Unresectable Cutaneous Squamous Cell Carcinoma of the Forehead With MLH1 Mutation Showing Dramatic Response to Programmed Cell Death Protein 1 Inhibitor Therapy
Citation: 20
Authors: Jed H., Steven, William C.
-
Macrocyclic Lactones Block Melanoma Growth, Metastases Development and Potentiate Activity of Anti–BRAF V600 Inhibitors
Citation: 8
Authors: Franck, Iotefa, Philippe, Eloise, Denis, Bernard, Anne-Françoise
-
Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma
Citation: 8
Authors: Georgia M., James, Jeff, J. Harrison, Alicia, Doreen, David, Joanne, Thomas
-
Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib to Allow Complete Surgical Resection in Patients With BRAF Mutated, Prior Unresectable Stage III or IV Melanoma) Trial
Citation: 6
Authors: Max F., E.A. Lisette, Jos A., Michel W.J.M., W. Martin C., J.V. Hans, Christian U., John B.A.G., Alexander C.J.
-
Immunosuppressive Agents and Their Role in Managing Immunotherapy Toxicities in Melanoma
Citation: 5
Authors: Romaana, Heather M., Paul D.
-
Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors
Citation: 3
Authors: Sarah E., Jeffrey A., Sunandana
-
Chronic Arsenic Poisoning Leading to Skin Malignancy in a Community
Citation: 3
Authors: Sharad, Vipin Ramesh, Suresh
-
Surgical Management of Primary Cutaneous Mucinous Carcinoma
Citation: 2
Authors: Steven A., Jiayi, Akash, Alexandra, Samih, Achilleas